0 XP   0   0   0

Intracellular Th










Financial Health of Intracellular Th




Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry




  Industry Rankings  


Intracellular Th
Buy, Hold or Sell?

Should you buy, hold or sell Intracellular Th?

I guess you are interested in Intracellular Th. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Intracellular Th

Let's start. I'm going to help you getting a better view of Intracellular Th. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Intracellular Th even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Intracellular Th is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Intracellular Th. The closing price on 2022-12-02 was $54.08 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Intracellular Th Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Intracellular Th.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Intracellular Th earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Intracellular Th to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of -74.5% means that $-0.74 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Intracellular Th:

  • The MRQ is -74.5%. The company is making a huge loss. -2
  • The TTM is -187.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-74.5%TTM-187.4%+113.0%
TTM-187.4%YOY-386.4%+199.0%
TTM-187.4%5Y-68,859.9%+68,672.4%
5Y-68,859.9%10Y-78,141.7%+9,281.9%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-74.5%0.4%-74.9%
TTM-187.4%0.3%-187.7%
YOY-386.4%0.2%-386.6%
5Y-68,859.9%-0.7%-68,859.2%
10Y-78,141.7%-0.1%-78,141.6%
1.1.2. Return on Assets

Shows how efficient Intracellular Th is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Intracellular Th to the Drug Manufacturers-Specialty & Generic industry mean.
  • -6.8% Return on Assets means that Intracellular Th generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Intracellular Th:

  • The MRQ is -6.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.8%TTM-10.8%+4.0%
TTM-10.8%YOY-10.3%-0.6%
TTM-10.8%5Y-10.6%-0.2%
5Y-10.6%10Y-10,926.9%+10,916.3%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.8%0.1%-6.9%
TTM-10.8%0.1%-10.9%
YOY-10.3%-0.1%-10.2%
5Y-10.6%-0.2%-10.4%
10Y-10,926.9%0.1%-10,927.0%
1.1.3. Return on Equity

Shows how efficient Intracellular Th is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Intracellular Th to the Drug Manufacturers-Specialty & Generic industry mean.
  • -7.8% Return on Equity means Intracellular Th generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Intracellular Th:

  • The MRQ is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.8%TTM-12.4%+4.5%
TTM-12.4%YOY-11.5%-0.8%
TTM-12.4%5Y-12.2%-0.2%
5Y-12.2%10Y-9.7%-2.5%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.8%0.6%-8.4%
TTM-12.4%0.4%-12.8%
YOY-11.5%0.4%-11.9%
5Y-12.2%-0.3%-11.9%
10Y-9.7%0.1%-9.8%

1.2. Operating Efficiency of Intracellular Th.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Intracellular Th is operating .

  • Measures how much profit Intracellular Th makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Intracellular Th to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of -74.4% means the company generated $-0.74  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Intracellular Th:

  • The MRQ is -74.4%. The company is operating very inefficient. -2
  • The TTM is -186.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-74.4%TTM-186.4%+112.0%
TTM-186.4%YOY-386.3%+199.9%
TTM-186.4%5Y-71,493.2%+71,306.8%
5Y-71,493.2%10Y-78,974.2%+7,481.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-74.4%2.5%-76.9%
TTM-186.4%1.6%-188.0%
YOY-386.3%2.7%-389.0%
5Y-71,493.2%1.8%-71,495.0%
10Y-78,974.2%0.8%-78,975.0%
1.2.2. Operating Ratio

Measures how efficient Intracellular Th is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 1.86 means that the operating costs are $1.86 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Intracellular Th:

  • The MRQ is 1.855. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.987. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.855TTM2.987-1.132
TTM2.987YOY4.894-1.907
TTM2.9875Y1,373.363-1,370.376
5Y1,373.36310Y1,566.524-193.162
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8551.473+0.382
TTM2.9871.456+1.531
YOY4.8941.398+3.496
5Y1,373.3631.374+1,371.989
10Y1,566.5241.191+1,565.333

1.3. Liquidity of Intracellular Th.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Intracellular Th is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 9.81 means the company has $9.81 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Intracellular Th:

  • The MRQ is 9.815. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.027. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.815TTM11.027-1.212
TTM11.027YOY14.427-3.401
TTM11.0275Y13.969-2.942
5Y13.96910Y20.324-6.355
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ9.8151.880+7.935
TTM11.0271.901+9.126
YOY14.4272.112+12.315
5Y13.9692.182+11.787
10Y20.3241.891+18.433
1.3.2. Quick Ratio

Measures if Intracellular Th is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Intracellular Th to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 15.29 means the company can pay off $15.29 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Intracellular Th:

  • The MRQ is 15.291. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.164. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.291TTM18.164-2.873
TTM18.164YOY24.872-6.708
TTM18.1645Y23.962-5.798
5Y23.96210Y33.757-9.795
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ15.2910.733+14.558
TTM18.1640.796+17.368
YOY24.8720.808+24.064
5Y23.9620.834+23.128
10Y33.7570.821+32.936

1.4. Solvency of Intracellular Th.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Intracellular Th assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Intracellular Th to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.12 means that Intracellular Th assets are financed with 12.4% credit (debt) and the remaining percentage (100% - 12.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Intracellular Th:

  • The MRQ is 0.124. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.117. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.124TTM0.117+0.006
TTM0.117YOY0.105+0.013
TTM0.1175Y0.114+0.003
5Y0.11410Y17.122-17.008
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1240.437-0.313
TTM0.1170.424-0.307
YOY0.1050.398-0.293
5Y0.1140.398-0.284
10Y17.1220.401+16.721
1.4.2. Debt to Equity Ratio

Measures if Intracellular Th is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Intracellular Th to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 14.1% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Intracellular Th:

  • The MRQ is 0.141. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.133. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.141TTM0.133+0.008
TTM0.133YOY0.117+0.016
TTM0.1335Y0.132+0.001
5Y0.13210Y0.379-0.246
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1410.652-0.511
TTM0.1330.675-0.542
YOY0.1170.623-0.506
5Y0.1320.684-0.552
10Y0.3790.697-0.318

2. Market Valuation of Intracellular Th

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Intracellular Th generates.

  • Above 15 is considered overpriced but always compare Intracellular Th to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of -82.19 means the investor is paying $-82.19 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Intracellular Th:

  • The EOD is -95.527. Company is losing money. -2
  • The MRQ is -82.191. Company is losing money. -2
  • The TTM is -70.535. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-95.527MRQ-82.191-13.336
MRQ-82.191TTM-70.535-11.656
TTM-70.535YOY-53.001-17.533
TTM-70.5355Y-49.703-20.832
5Y-49.70310Y-82.616+32.913
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD-95.527-0.124-95.403
MRQ-82.191-0.437-81.754
TTM-70.535-0.102-70.433
YOY-53.00115.340-68.341
5Y-49.7037.916-57.619
10Y-82.6167.700-90.316
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Intracellular Th.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Intracellular Th:

  • The MRQ is -132.464. Very Bad. -2
  • The TTM is 93.779. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ-132.464TTM93.779-226.243
TTM93.779YOY203.423-109.643
TTM93.7795Y119.191-25.412
5Y119.19110Y-4,771.437+4,890.628
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-132.4640.012-132.476
TTM93.7790.010+93.769
YOY203.4230.004+203.419
5Y119.1910.010+119.181
10Y-4,771.4370.021-4,771.458

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Intracellular Th is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 6.42 means the investor is paying $6.42 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Intracellular Th:

  • The EOD is 7.457. Seems overpriced? -1
  • The MRQ is 6.416. Seems overpriced? -1
  • The TTM is 8.247. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD7.457MRQ6.416+1.041
MRQ6.416TTM8.247-1.831
TTM8.247YOY5.998+2.249
TTM8.2475Y5.989+2.258
5Y5.98910Y7.597-1.608
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD7.4571.415+6.042
MRQ6.4161.586+4.830
TTM8.2472.019+6.228
YOY5.9982.230+3.768
5Y5.9891.895+4.094
10Y7.5971.505+6.092
2. Total Gains per Share

2.4. Latest News of Intracellular Th

Does Intracellular Th still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Intracellular Th to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-11-23
15:55
Can Intra-Cellular (ITCI) Climb 33% to Reach the Level Wall Street Analysts Expect?Read
2022-11-07
15:55
How Much Upside is Left in Intra-Cellular (ITCI)? Wall Street Analysts Think 33%Read
2022-11-05
14:20
The three-year returns have been fantastic for Intra-Cellular Therapies (NASDAQ:ITCI) shareholders despite underlying losses increasingRead

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Intracellular Th.

3.1. Institutions holding Intracellular Th

Institutions are holding 90.617% of the shares of Intracellular Th.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30FMR Inc10.91120.058810333063-621647-5.6747
2022-06-30Vanguard Group Inc8.53230.01380801982917293.7457
2022-06-30Wasatch Advisors Inc.5.69271.94545391065-2086803-27.9064
2022-06-30Wellington Management Company LLP4.71310.051344633584021989.9035
2022-06-30Bellevue Group AG3.53682.70263349379-80240-2.3396
2022-06-30AllianceBernstein L.P.2.23080.0551211258720178772130.5849
2022-06-30State Street Corporation2.02720.006619198151272857.1009
2022-06-30Lord, Abbett & Co LLC1.95450.37361850949-130407-6.5817
2022-06-30Franklin Resources Inc1.79480.0481169973010340.0609
2022-06-30Holocene Advisors, LP1.71850.5611627408904684125.177
2022-06-30Geode Capital Management, LLC1.67730.013315883991174427.9841
2022-06-30Suvretta Capital Management, LLC1.41362.90571338700-193223-12.6131
2022-06-30Victory Capital Management Inc.1.19830.0738113485020252821.723
2022-06-30Millennium Management LLC1.09530.0367103727731180842.9802
2022-06-30Adage Capital Partners Gp LLC1.05940.1313100327115327118.0319
2022-06-30Northern Trust Corp0.98790.0114935572615947.0475
2022-06-30Polar Capital Holdings PLC0.93820.297988853736709470.3996
2022-06-30Schroder Investment Management Group0.88750.0747840516-143397-14.5742
2022-06-30Amvescap Plc.0.86190.014181618733780270.613
2022-06-30TimesSquare Capital Management, LLC0.84560.6374800838-76190-8.6873
Total 54.076910.011851211699+1964439+3.8%

3.2. Funds holding Intracellular Th

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-09-30Fidelity Growth Compy Commingled Pl 34.25070.4023402547469130.172
2022-09-30BB Biotech AG Ord3.47565.49733291479-66940-1.9932
2022-09-30Fidelity® Growth Company3.32640.3751315011900
2022-10-31Vanguard Total Stock Mkt Idx Inv2.70580.01012562422252950.997
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr2.67910.01122537127384041.5369
2022-10-31Vanguard Health Care Inv2.42360.2248229519600
2022-10-31Vanguard Small Cap Index2.3150.08562192367352031.6319
2022-10-31iShares Russell 2000 ETF2.1470.1743203322666500.3281
2022-09-30Lord Abbett Developing Growth A1.43722.5652136108400
2022-10-31Vanguard Small Cap Growth Index Inv1.34080.2071269732227861.8273
2022-10-31Vanguard Extended Market Index Investor1.25180.0646118551292460.786
2022-09-30Wasatch Ultra Growth1.22793.9408116282617896118.1896
2022-09-30Fidelity® Series Growth Company1.0040.406495080900
2022-09-30Franklin Biotechnology Discv A(acc)USD1.00152.549894845800
2022-09-30Fidelity® Growth Company K60.91770.4161869043-6913-0.7892
2022-10-31Vanguard Explorer Inv0.82480.18678107200
2022-09-30AB Small Cap Growth A0.81390.9425770740-7910-1.0159
2022-10-31iShares Russell 2000 Growth ETF0.7710.3459730191-3424-0.4667
2022-08-31Fidelity® Small Cap Index0.74410.1889704640144732.097
2022-04-30Pictet-Biotech P USD0.73052.383691802-85400-10.9881
Total 35.388420.976933513319+167344+0.5%

3.3. Insider Transactions

Insiders are holding 2.446% of the shares of Intracellular Th.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-09-21Lawrence J. HinelineSELL6516445.63
2022-08-11Nostrand Robert L VanSELL3000057.139043
2022-05-12Joel S MarcusSELL100005554233
2022-04-08Mark NeumannSELL8634864.3745339
2022-03-18Rory B RiggsSELL2063761.18
2022-03-16Rory B RiggsSELL6453459.27
2022-03-07Joel S MarcusSELL500054.52
2022-03-04Suresh K DurgamSELL386055.52
2022-03-02Suresh K DurgamSELL417756.98
2022-02-24Mark NeumannSELL790652.21
2022-02-24Suresh K DurgamSELL404652.27
2022-02-24Sharon MatesSELL2258951.98
2022-02-24Lawrence J HinelineSELL745451.97
2022-02-22Lawrence J HinelineSELL1044355.4
2022-02-22Mark NeumannSELL1113955.29
2022-02-22Sharon MatesSELL2784755.39
2022-02-22Suresh K DurgamSELL417755.29
2022-01-18Suresh K DurgamSELL622342.03
2022-01-10Lawrence J HinelineSELL1963940.76
2022-01-10Mark NeumannSELL2094840.78

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Intracellular Th compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3980.524-176%-0.590+48%0.193-306%0.177-326%
Book Value Growth---0.0540.039-237%-0.099+85%0.002-2743%-2.077+3772%
Book Value Per Share--7.2526.932+5%6.116+19%4.954+46%3.716+95%
Book Value Per Share Growth---0.0550.039-241%-0.099+80%0.002-2895%-2.077+3681%
Current Ratio--9.81511.027-11%14.427-32%13.969-30%20.324-52%
Debt To Asset Ratio--0.1240.117+5%0.105+18%0.114+8%17.122-99%
Debt To Equity Ratio--0.1410.133+6%0.117+20%0.132+6%0.379-63%
Dividend Per Share----0%-0%-0%-0%
Eps---0.566-0.789+39%-0.686+21%-0.559-1%-0.372-34%
Eps Growth--0.6200.135+360%-0.070+111%-0.024+104%-0.030+105%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Net Profit Margin---0.745-1.874+152%-3.864+419%-688.599+92390%-781.417+104857%
Operating Margin---0.744-1.864+150%-3.863+419%-714.932+95929%-789.742+105977%
Operating Ratio--1.8552.987-38%4.894-62%1373.363-100%1566.524-100%
Pb Ratio7.457+14%6.4168.247-22%5.998+7%5.989+7%7.597-16%
Pe Ratio-95.527-16%-82.191-70.535-14%-53.001-36%-49.703-40%-82.616+1%
Peg Ratio---132.46493.779-241%203.423-165%119.191-211%-4771.437+3502%
Price Per Share54.080+14%46.53054.285-14%35.958+29%29.045+60%23.959+94%
Price To Total Gains Ratio-135.743-16%-116.792-62.376-47%-61.811-47%-46.201-60%-79.302-32%
Profit Growth--61.85113.427+361%-6.973+111%-2.385+104%3964.452-98%
Quick Ratio--15.29118.164-16%24.872-39%23.962-36%33.757-55%
Return On Assets---0.068-0.108+58%-0.103+50%-0.106+55%-109.269+159593%
Return On Equity---0.078-0.124+58%-0.115+48%-0.122+56%-0.097+24%
Revenue Growth--0.2340.256-9%0.228+3%-0.002+101%-0.275+218%
Total Gains Per Share---0.3980.524-176%-0.590+48%0.193-306%0.177-326%
Total Gains Per Share Growth--0.876-1.071+222%-1.866+313%-0.962+210%2.229-61%
Usd Book Value--685422000.000654564918.750+5%577337997.250+19%467680468.850+47%350799302.600+95%
Usd Book Value Change Per Share---0.3980.524-176%-0.590+48%0.193-306%0.177-326%
Usd Book Value Per Share--7.2526.932+5%6.116+19%4.954+46%3.716+95%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.566-0.789+39%-0.686+21%-0.559-1%-0.372-34%
Usd Price Per Share54.080+14%46.53054.285-14%35.958+29%29.045+60%23.959+94%
Usd Profit---53508000.000-74490984.250+39%-64772726.750+21%-52820981.450-1%-35143240.350-34%
Usd Revenue--71870000.00047327542.250+52%17148900.500+319%13416760.150+436%5190545.950+1285%
Usd Total Gains Per Share---0.3980.524-176%-0.590+48%0.193-306%0.177-326%
 EOD+2 -3MRQTTM+19 -13YOY+25 -75Y+16 -1610Y+18 -15

4.2. Fundamental Score

Let's check the fundamental score of Intracellular Th based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-95.527
Price to Book Ratio (EOD)Between0-17.457
Net Profit Margin (MRQ)Greater than0-0.745
Operating Margin (MRQ)Greater than0-0.744
Quick Ratio (MRQ)Greater than115.291
Current Ratio (MRQ)Greater than19.815
Debt to Asset Ratio (MRQ)Less than10.124
Debt to Equity Ratio (MRQ)Less than10.141
Return on Equity (MRQ)Greater than0.15-0.078
Return on Assets (MRQ)Greater than0.05-0.068
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Intracellular Th based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.144
Ma 20Greater thanMa 5051.953
Ma 50Greater thanMa 10048.675
Ma 100Greater thanMa 20050.619
OpenGreater thanClose53.000
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2021-09-302021-12-312022-03-312022-06-302022-09-30
Depreciation and Amortization  13413147241711172-376-204



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets781,999
Total Liabilities96,577
Total Stockholder Equity685,422
 As reported
Total Liabilities 96,577
Total Stockholder Equity+ 685,422
Total Assets = 781,999

Assets

Total Assets781,999
Total Current Assets759,756
Long-term Assets759,756
Total Current Assets
Cash And Cash Equivalents 135,358
Short-term Investments 493,383
Net Receivables 61,538
Inventory 23,597
Other Current Assets 45,880
Total Current Assets  (as reported)759,756
Total Current Assets  (calculated)759,756
+/-0
Long-term Assets
Property Plant Equipment 22,157
Other Assets 86
Long-term Assets  (as reported)22,243
Long-term Assets  (calculated)22,243
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities77,410
Long-term Liabilities19,167
Total Stockholder Equity685,422
Total Current Liabilities
Short-term Debt 7,245
Accounts payable 14,219
Other Current Liabilities 55,946
Total Current Liabilities  (as reported)77,410
Total Current Liabilities  (calculated)77,410
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt19,167
Long-term Liabilities  (as reported)19,167
Long-term Liabilities  (calculated)19,167
+/-0
Total Stockholder Equity
Retained Earnings -1,433,460
Capital Surplus 2,124,369
Total Stockholder Equity (as reported)685,422
Total Stockholder Equity (calculated)690,909
+/- 5,487
Other
Capital Stock9
Cash and Short Term Investments 628,741
Common Stock Shares Outstanding 94,517
Common Stock Total Equity9
Liabilities and Stockholders Equity 781,999
Net Debt -108,946
Net Invested Capital 685,422
Net Tangible Assets 685,422
Net Working Capital 682,346
Short Long Term Debt Total 26,412



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302011-12-31
> Total Assets 
23,595
0
19,824
4
0
47,336
38,449
146,637
141,343
137,609
131,112
237,128
213,404
513,122
484,104
463,662
447,603
542,572
388,903
372,292
349,540
334,191
471,487
445,639
412,074
385,587
357,206
342,973
309,863
280,523
251,186
481,243
440,931
771,294
717,314
674,489
625,697
556,976
489,922
868,580
811,906
781,999
781,999811,906868,580489,922556,976625,697674,489717,314771,294440,931481,243251,186280,523309,863342,973357,206385,587412,074445,639471,487334,191349,540372,292388,903542,572447,603463,662484,104513,122213,404237,128131,112137,609141,343146,63738,44947,3360419,824023,595
   > Total Current Assets 
0
0
0
4
0
47,130
38,249
146,371
141,208
137,481
130,986
236,497
212,611
512,265
483,256
462,859
446,808
541,819
388,200
371,611
348,835
333,435
469,215
443,154
409,661
383,253
355,439
321,128
288,342
259,457
230,324
460,973
418,573
744,866
690,904
649,100
601,303
533,243
467,281
848,342
789,206
759,756
759,756789,206848,342467,281533,243601,303649,100690,904744,866418,573460,973230,324259,457288,342321,128355,439383,253409,661443,154469,215333,435348,835371,611388,200541,819446,808462,859483,256512,265212,611236,497130,986137,481141,208146,37138,24947,13004000
       Cash And Cash Equivalents 
13,694
0
15,646
4
0
44,072
35,151
143,618
91,140
68,915
61,325
100,802
71,418
332,828
47,159
37,241
51,973
200,388
48,642
23,598
29,590
52,341
37,790
74,421
69,767
69,777
54,948
64,091
91,763
102,163
107,637
179,593
129,290
300,989
60,046
129,980
121,030
106,126
92,365
129,295
77,235
135,358
135,35877,235129,29592,365106,126121,030129,98060,046300,989129,290179,593107,637102,16391,76364,09154,94869,77769,76774,42137,79052,34129,59023,59848,642200,38851,97337,24147,159332,82871,418100,80261,32568,91591,140143,61835,15144,0720415,646013,694
       Short-term Investments 
9,200
0
3,500
0
0
2,000
2,000
2,000
49,355
67,067
68,321
134,424
132,571
177,904
428,041
418,828
390,717
337,406
335,458
344,183
313,038
275,781
426,541
362,584
333,997
306,211
292,583
248,731
193,537
153,271
116,373
269,361
278,469
420,959
597,402
481,985
433,727
371,158
319,968
642,553
600,594
493,383
493,383600,594642,553319,968371,158433,727481,985597,402420,959278,469269,361116,373153,271193,537248,731292,583306,211333,997362,584426,541275,781313,038344,183335,458337,406390,717418,828428,041177,904132,571134,42468,32167,06749,3552,0002,0002,000003,50009,200
       Net Receivables 
0
0
0
0
0
251
336
168
219
124
52
3
9
0
31
98
98
1
94
68
62
6
0
0
0
0
0
615
615
351
351
1,351
2,353
7,481
10,765
13,662
15,188
16,934
20,156
32,832
46,976
61,538
61,53846,97632,83220,15616,93415,18813,66210,7657,4812,3531,35135135161561500000662689419898310935212421916833625100000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,391
2,335
2,947
7,056
7,579
7,769
8,167
7,948
7,893
25,022
23,597
23,59725,0227,8937,9488,1677,7697,5797,0562,9472,3351,3910000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
206
200
266
135
128
125
631
793
857
847
803
794
753
703
681
705
755
2,271
2,485
2,413
2,334
1,768
21,845
21,521
21,066
20,863
20,270
22,357
26,428
26,409
25,388
24,393
23,733
22,641
20,238
22,700
22,243
22,24322,70020,23822,64123,73324,39325,38826,40926,42822,35720,27020,86321,06621,52121,8451,7682,3342,4132,4852,27175570568170375379480384785779363112512813526620020600000
       Property Plant Equipment 
67
0
58
0
0
76
68
65
64
57
55
560
722
786
776
731
719
678
628
606
629
680
1,137
1,350
1,275
1,196
1,160
21,230
20,905
20,715
20,512
20,184
22,271
26,342
26,323
25,302
24,307
23,647
22,555
20,152
22,614
22,157
22,15722,61420,15222,55523,64724,30725,30226,32326,34222,27120,18420,51220,71520,90521,2301,1601,1961,2751,3501,1376806296066286787197317767867225605557646568760058067
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
36,500
44,700
0
9,200
8,300
0
0
0
21,600
19,500
41,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000041,30019,50021,6000008,3009,200044,70036,50000000000000
       Long-term Assets Other 
0
0
0
0
0
131
132
200
71
71
71
71
71
72
72
72
76
76
76
76
76
76
76
77
79
79
79
86
86
86
86
86
86
86
86
86
86
86
86
86
86
86
8686868686868686868686868686867979797776767676767676727272717171717120013213100000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,058
1,058
1,058
1,058
529
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000005291,0581,0581,0581,0580000000000000000000000
> Total Liabilities 
5,703
0
18,196
26
33
7,775
6,834
3,912
2,739
3,578
10,557
14,753
9,839
11,268
7,861
10,917
21,640
143,254
13,401
19,265
9,874
14,751
17,050
22,450
21,686
31,962
39,492
54,358
53,094
53,643
56,179
50,794
61,401
61,898
60,454
62,339
72,111
70,219
72,031
75,830
89,709
96,577
96,57789,70975,83072,03170,21972,11162,33960,45461,89861,40150,79456,17953,64353,09454,35839,49231,96221,68622,45017,05014,7519,87419,26513,401143,25421,64010,9177,86111,2689,83914,75310,5573,5782,7393,9126,8347,775332618,19605,703
   > Total Current Liabilities 
4,036
0
18,196
26
33
7,775
6,834
3,912
2,739
3,578
10,557
14,593
9,318
10,387
6,264
8,947
19,381
140,690
10,532
16,319
6,963
11,875
14,210
19,653
18,935
29,129
36,299
33,499
32,526
33,373
36,224
31,076
40,243
38,029
36,853
39,702
50,422
49,896
53,356
59,074
70,634
77,410
77,41070,63459,07453,35649,89650,42239,70236,85338,02940,24331,07636,22433,37332,52633,49936,29929,12918,93519,65314,21011,8756,96316,31910,532140,69019,3818,9476,26410,3879,31814,59310,5573,5782,7393,9126,8347,775332618,19604,036
       Short-term Debt 
0
0
0
0
9
0
0
0
0
0
0
0
0
0
0
125,000
125,000
125,000
0
0
0
0
0
0
0
0
0
2,873
2,263
2,287
3,187
3,211
3,974
5,267
5,542
5,573
5,595
6,082
6,732
7,636
7,743
7,245
7,2457,7437,6366,7326,0825,5955,5735,5425,2673,9743,2113,1872,2872,2632,873000000000125,000125,000125,000000000000090000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
125,000
125,000
125,000
0
0
0
0
0
0
0
0
0
2,873
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000002,873000000000125,000125,000125,000000000000000000
       Accounts payable 
596
0
42
26
24
4,027
3,395
2,143
416
504
2,053
4,574
4,911
705
1,633
1,959
3,890
5,417
3,755
7,158
1,775
4,408
6,174
10,039
5,379
10,453
13,961
8,574
5,633
6,231
7,425
10,994
5,473
8,569
5,502
8,721
15,941
12,031
8,691
11,649
10,749
14,219
14,21910,74911,6498,69112,03115,9418,7215,5028,5695,47310,9947,4256,2315,6338,57413,96110,4535,37910,0396,1744,4081,7757,1583,7555,4173,8901,9591,6337054,9114,5742,0535044162,1433,3954,0272426420596
       Other Current Liabilities 
3,440
0
2,982
0
0
3,331
3,439
1,769
2,323
3,074
8,504
10,018
4,407
9,682
4,631
6,987
15,492
10,272
6,778
9,161
5,187
7,467
8,036
9,614
13,556
18,676
22,338
22,052
24,631
24,855
25,612
16,871
30,796
24,192
25,810
25,408
28,886
31,783
37,933
39,789
52,142
55,946
55,94652,14239,78937,93331,78328,88625,40825,81024,19230,79616,87125,61224,85524,63122,05222,33818,67613,5569,6148,0367,4675,1879,1616,77810,27215,4926,9874,6319,6824,40710,0188,5043,0742,3231,7693,4393,331002,98203,440
   > Long-term Liabilities 
0
0
0
26,170
26,170
0
0
0
0
0
0
160
521
881
1,597
1,971
2,259
2,564
2,869
2,947
2,911
2,876
2,840
2,797
2,751
2,833
3,192
20,859
20,568
20,270
19,955
19,718
21,158
23,870
23,600
22,637
21,689
20,324
18,675
16,756
19,075
19,167
19,16719,07516,75618,67520,32421,68922,63723,60023,87021,15819,71819,95520,27020,56820,8593,1922,8332,7512,7972,8402,8762,9112,9472,8692,5642,2591,9711,59788152116000000026,17026,170000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-9
0
0
0
0
0
0
0
0
0
0
-125,000
-125,000
-125,000
0
0
0
0
0
0
0
0
0
20,859
20,568
20,270
19,955
19,718
21,158
23,870
23,600
22,637
21,689
20,324
18,675
16,756
19,075
19,167
19,16719,07516,75618,67520,32421,68922,63723,60023,87021,15819,71819,95520,27020,56820,859000000000-125,000-125,000-125,0000000000000-90000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,058
1,058
1,058
1,058
529
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000005291,0581,0581,0581,0580000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,568
20,270
0
0
0
0
0
0
0
0
0
0
0
0
00000000000020,27020,5680000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
521
881
1,597
0
0
0
2,869
0
0
0
2,840
2,797
2,751
2,833
3,192
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000003,1922,8332,7512,7972,8400002,8690001,597881521000000000000
> Total Stockholder Equity
17,892
0
1,628
-22
-33
39,561
31,615
142,725
138,604
134,032
120,555
222,375
203,565
501,854
476,243
452,744
425,963
399,318
375,503
353,027
339,666
319,440
454,437
423,189
390,387
353,625
317,715
288,614
256,768
226,880
195,007
430,448
379,530
709,396
656,860
612,150
553,586
486,756
417,891
792,750
722,197
685,422
685,422722,197792,750417,891486,756553,586612,150656,860709,396379,530430,448195,007226,880256,768288,614317,715353,625390,387423,189454,437319,440339,666353,027375,503399,318425,963452,744476,243501,854203,565222,375120,555134,032138,604142,72531,61539,561-33-221,628017,892
   Common Stock
11
0
11
1
1
2
2
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
6
6
6
6
7
7
8
8
8
8
8
8
9
9
9
99988888877666655555444444444433333221111011
   Retained Earnings Total Equity-1,433,460-1,379,952-1,293,349-1,221,230-1,135,496-1,058,588-989,844-937,104-876,405-821,221-757,509-710,098-669,516-634,653-597,212-562,376-521,628-480,105-442,729-407,249-377,040-354,170-336,409-309,475-281,990-251,725-220,891-193,049-164,215-132,054-110,543-88,256-73,057-66,641-62,108-57,564-49,524-43-32000
   Accumulated Other Comprehensive Income 
0
0
0
0
-43
-3,236
-3,232
-3,238
-48
-67
-105
-34
-53
-19
-590
-49
60
-171
-317
-292
-316
-220
-799
-1,240
-1,029
-846
-668
-67
232
199
128
-145
1,168
769
481
247
176
94
0
-3,328
-4,802
0
0-4,802-3,3280941762474817691,168-145128199232-67-668-846-1,029-1,240-799-220-316-292-317-17160-49-590-19-53-34-105-67-48-3,238-3,232-3,236-430000
   Capital Surplus 
0
0
0
10
10
89,083
89,178
204,830
205,290
207,153
208,912
332,948
335,669
666,084
669,878
673,680
677,624
681,475
685,291
689,723
694,147
696,695
862,480
867,152
871,517
876,094
880,753
885,888
891,184
896,191
904,972
1,188,096
1,199,576
1,585,024
1,593,476
1,601,739
1,611,989
1,622,150
1,639,476
2,089,418
2,106,942
2,124,369
2,124,3692,106,9422,089,4181,639,4761,622,1501,611,9891,601,7391,593,4761,585,0241,199,5761,188,096904,972896,191891,184885,888880,753876,094871,517867,152862,480696,695694,147689,723685,291681,475677,624673,680669,878666,084335,669332,948208,912207,153205,290204,83089,17889,0831010000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
-23
52
92,319
92,410
208,068
205,290
207,153
208,912
332,948
335,669
666,084
669,878
673,680
677,624
681,475
685,291
689,723
694,147
696,695
862,480
867,152
871,517
876,094
880,753
885,888
891,184
896,191
904,972
1,188,096
1,199,576
1,585,024
1,593,476
1,601,739
1,611,989
1,622,150
1,639,112
2,089,418
2,106,942
2,118,873
2,118,8732,106,9422,089,4181,639,1121,622,1501,611,9891,601,7391,593,4761,585,0241,199,5761,188,096904,972896,191891,184885,888880,753876,094871,517867,152862,480696,695694,147689,723685,291681,475677,624673,680669,878666,084335,669332,948208,912207,153205,290208,06892,41092,31952-23000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue83,803
Cost of Revenue-8,035
Gross Profit75,76875,768
 
Operating Income (+$)
Gross Profit75,768
Operating Expense-369,491
Operating Income-285,688-293,723
 
Operating Expense (+$)
Research Development88,846
Selling General Administrative272,611
Selling And Marketing Expenses-
Operating Expense369,491361,457
 
Net Interest Income (+$)
Interest Income1,568
Interest Expense-0
Net Interest Income1,5681,568
 
Pretax Income (+$)
Operating Income-285,688
Net Interest Income1,568
Other Non-Operating Income Expenses1,568
Income Before Tax (EBT)-284,120-287,256
EBIT - interestExpense = -284,131
-284,131
-284,126
Interest Expense0
Earnings Before Interest and Taxes (ebit)-284,131-284,120
Earnings Before Interest and Taxes (ebitda)-283,598
 
After tax Income (+$)
Income Before Tax-284,120
Tax Provision-6
Net Income From Continuing Ops-284,126-284,126
Net Income-284,126
Net Income Applicable To Common Shares-284,126
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses377,526
Total Other Income/Expenses Net1,568-3,136
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.